• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.

作者信息

Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G

机构信息

Institute for Biochemistry and Endocrinology, University of Giessen, Germany.

出版信息

Anticancer Res. 1997 Jul-Aug;17(4B):3153-6.

PMID:9329624
Abstract

Proliferating and tumor cells express a certain isoenzyme of pyruvate kinase, called PK type M2. This isoenzyme can be isolated in an active tetrameric and an inactive dimeric form. We have termed this form tumor type M2-PK. This tumor type pyruvate kinase can be quantified by a specific ELISA in blood sera and tumor homogenates. In this study we have compared 26 normal colon mucosa and colon cancer specimens from the same patients. The total specific pyruvate kinase activity and the amount of the tumour type M2-PK measured by ELISA was increased in the tumor samples compared to the normal colon mucosa of the same patient. In normal colon mucosa the specific PK-activity ranged between 0.21 and 1.25 U/mg protein whereas in colon carcinoma we found activities between 0.99 and 7.08 U/mg. The amount of tumor M2-PK measured by ELISA ranged between 0.82 and 27.10 U/mg protein in normal colon mucosa and between 1.96 and 242.40 U/mg protein in colon carcinoma. The tumor M2-PK content in the serum of 666 healthy blood donors was measured by ELISA and compared to sera from 15 colon carcinoma patients and showed a highly significant difference (Mann-Whitney rank sum test, p < 0.001). The values for the 50%-percentiles (median) of blood donors were 10.8 U/ml and 55.0 U/ml for colon carcinoma.

摘要

相似文献

1
Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
Anticancer Res. 1997 Jul-Aug;17(4B):3153-6.
2
Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).肾细胞癌(RCC)标志物:M2型丙酮酸激酶的二聚体形式(Tu M2-PK)。
Anticancer Res. 1999 Jul-Aug;19(4A):2583-90.
3
Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).肿瘤型丙酮酸激酶(肿瘤M2-PK)检测中的分析前问题。
Anticancer Res. 2003 Mar-Apr;23(2A):1127-30.
4
The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.代谢标志物肿瘤型丙酮酸激酶M2(肿瘤M2-PK)在巴雷特食管的化生-发育异常-腺癌序列中表达增加。
J Clin Pathol. 2004 Nov;57(11):1156-9. doi: 10.1136/jcp.2004.018150.
5
Quantitative detection of tumor M2-PK in serum and plasma.血清和血浆中肿瘤M2-PK的定量检测
Anticancer Res. 1999 Jul-Aug;19(4A):2753-7.
6
Value of tumor M2-PK in thyroid carcinoma: a pilot study.肿瘤M2-PK在甲状腺癌中的价值:一项初步研究。
Anticancer Res. 2003 Nov-Dec;23(6D):5237-40.
7
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells.肿瘤细胞代谢转变中的肿瘤M2-丙酮酸激酶与谷氨酰胺分解酶
Anticancer Res. 2000 Nov-Dec;20(6D):5151-4.
8
Tumor type M2 pyruvate kinase expression in advanced breast cancer.晚期乳腺癌中肿瘤类型M2丙酮酸激酶的表达
Anticancer Res. 2000 Nov-Dec;20(6D):5077-82.
9
The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.丙酮酸激酶同工酶肿瘤M2(Tu M2-PK)作为肾癌的肿瘤标志物。
Anticancer Res. 1999 Jul-Aug;19(4A):2599-601.
10
Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.评估丙酮酸激酶同工酶肿瘤型(Tu M2-PK)作为宫颈癌肿瘤标志物的价值。
J Obstet Gynaecol Res. 2004 Jun;30(3):193-6. doi: 10.1111/j.1447-0756.2004.00187.x.

引用本文的文献

1
MicroRNA-122 regulates inflammatory and autophagic proteins by downregulating pyruvate kinase M2 in non-alcoholic fatty liver disease.微小RNA-122通过下调非酒精性脂肪性肝病中的丙酮酸激酶M2来调节炎症和自噬蛋白。
Mol Cell Biochem. 2025 May;480(5):3067-3078. doi: 10.1007/s11010-024-05174-y. Epub 2024 Dec 4.
2
Single-Cell FISH Analysis Reveals Distinct Shifts in PKM Isoform Populations during Drug Resistance Acquisition.单细胞荧光原位杂交分析揭示了药物耐药性获得过程中 PKM 同工型群体的明显变化。
Biomolecules. 2022 Aug 6;12(8):1082. doi: 10.3390/biom12081082.
3
The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1.
C 端酸性尾巴调节 HMGB1 的抗癌特性。
Int J Mol Sci. 2022 Jul 17;23(14):7865. doi: 10.3390/ijms23147865.
4
Tumor M2-PK: A novel urine marker of bladder cancer.肿瘤 M2-PK:膀胱癌的一种新型尿液标志物。
PLoS One. 2019 Jun 27;14(6):e0218737. doi: 10.1371/journal.pone.0218737. eCollection 2019.
5
Down-Regulation of Nfatc1 Suppresses Proliferation, Migration, Invasion, and Warburg Effect in Prostate Cancer Cells.NFATC1 的下调抑制前列腺癌细胞的增殖、迁移、侵袭和瓦博格效应。
Med Sci Monit. 2019 Feb 28;25:1572-1581. doi: 10.12659/MSM.910998.
6
The Krebs Cycle Connection: Reciprocal Influence Between Alternative Splicing Programs and Cell Metabolism.三羧酸循环关联:可变剪接程序与细胞代谢之间的相互影响
Front Oncol. 2018 Sep 26;8:408. doi: 10.3389/fonc.2018.00408. eCollection 2018.
7
Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression.丙酮酸激酶 M2 型(PKM2)过表达通过上调 CCND1 和下调 CDKN1A 表达调控细胞周期进程促进卵巢癌细胞生长和存活。
Med Sci Monit. 2018 May 12;24:3103-3112. doi: 10.12659/MSM.907490.
8
Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.评估肿瘤 M2-丙酮酸激酶(Tumor M2-PK)作为胰腺癌的生物标志物。
World J Surg Oncol. 2018 Mar 14;16(1):56. doi: 10.1186/s12957-018-1360-3.
9
Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.结直肠癌中与能量代谢相关的可变剪接转录本的差异表达
BMC Genomics. 2016 Dec 28;17(Suppl 14):1011. doi: 10.1186/s12864-016-3351-5.
10
Quantitative label-free mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue representing the invasive cutaneous malignant melanoma proteome.对代表侵袭性皮肤恶性黑色素瘤蛋白质组的福尔马林固定、石蜡包埋组织进行无标记定量质谱分析。
Oncol Lett. 2016 Nov;12(5):3296-3304. doi: 10.3892/ol.2016.5101. Epub 2016 Sep 7.